BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 18083230)

  • 21. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line.
    Yeheskely-Hayon D; Regev R; Eytan GD; Dann EJ
    Leuk Res; 2005 Jul; 29(7):793-802. PubMed ID: 15927675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
    Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C; Krystal G; Dent P; Grant S
    Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
    Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
    Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
    Subhashini J; Mahipal SV; Reddanna P
    Cancer Lett; 2005 Jun; 224(1):31-43. PubMed ID: 15911099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of celecoxib on enhancing the chemotherapic sensitivity of hydroxyurea to K562 cells and its mechanism].
    Liu DS; Zhang GS
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):495-9. PubMed ID: 16137030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
    Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
    Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z; Sampath J; Fukuda S; Pelus LM
    Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib.
    Jun HJ; Kim YM; Park SY; Park JS; Lee EJ; Choi SA; Pyo H
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):225-34. PubMed ID: 19695440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.
    Dharmapuri G; Doneti R; Philip GH; Kalle AM
    Leuk Res; 2015 Jul; 39(7):696-701. PubMed ID: 25916699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.
    Zhang Z; Lai GH; Sirica AE
    Hepatology; 2004 Apr; 39(4):1028-37. PubMed ID: 15057907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.